Healthcare
OptimizeRx Corporation(OPRX)
Live Price
Offline$4.98
-1.97% today
Window Change
-4.05%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $130.00M
- Revenue Growth
- +18.8%
- EPS Growth
- +125.5%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OptimizeRx Corporation (OPRX) is a Healthcare stock with a market cap of $130.00M and listed on NASDAQ. The stock last traded around $4.98 and down 4.0% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +18.8%, EPS growth of +125.5%, a dividend yield of 0.0%. What stands out right now is revenue +18.8%, EPS +125.5%, free cash flow +290.6% with operating margin 11.0% and ROIC 5.6%. Valuation is more restrained than many high-expectation growth names at P/E 24.4 and price/sales 1.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines OPRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+18.8% vs +7.6% peer median
Operating Margin
Below sector median
+11.0% vs +19.4% peer median
P/E
Below sector median
24.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +18.8% and EPS at +125.5%, with operating margin around 11.0%.
Benchmark Edge
OPRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OPRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OPRX Max Drawdown
-7.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OPRX and SPY.
Company Overview
OptimizeRx Corporation
NASDAQ Capital Market
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
- Leadership
- Stephen L. Silvestro
- IPO Date
- Nov 28, 2007
- Employees
- 128
- Street Address
- 400 Water Street
- Mailing
- Waltham, MI, 48307
- Region
- Waltham, MI, US
- Reporting Currency
- USD
- Investor Line
- 248 651 6568
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.4
- EV/EBITDA
- 7.8
- Price/Sales
- 1.1
- Price/Book
- 1.0
Growth
- Revenue
- +18.8%
- EPS
- +125.5%
- Free Cash Flow
- +290.6%
Profitability
- Gross Margin
- 63.3%
- Operating Margin
- 11.0%
- Net Margin
- 4.7%
- ROE
- 4.2%
- ROIC
- 5.6%
Balance Sheet
- Debt/Equity
- 0.20
- Current Ratio
- 3.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.